MOLOGEN AG: Sale of the essential assets
MOLOGEN AG / Key word(s): Insolvency
Mologen AG - Sale of the essential assets
The insolvency administrator of Mologen AG (WKN A2LQ90) has accepted the offer to sell a substantial part of Mologen's assets (in particular delvopments associated with Lefitolimod and Enandim) to Gilead Sciences Inc. The purchase price will probably enable a dividend for creditors in the insolvency but will not be sufficient to satisfy all insolvency claims in full.
Please note: Claims arising from the convertible bonds 2016/2024 and 2017/2025 can only be filed through the joint representative of the bondholders, Dr. Marc Liebscher, c/o Dr. Späth & Partner Rechtsanwälte, Kurfürstendamm 102, 10711 Berlin."
08-May-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||030 / 841788-0|
|Fax:||030 / 841788-50|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1039707|
|End of Announcement||DGAP News Service|